Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lukas BiomedicalROCO:6814 66 PS Ratio is 5.73 as of Jul. 27, 2026, which is 7% below its 10-year median of 6.18. GuruFocus rates ROCO:6814 with a GF Score™ of 66/100 and a GF Value™ of NT$21.75 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 929 Biotechnology companies, Lukas Biomedical ranks better than 62% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lukas Biomedical's share price is NT$24.55.
Lukas Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$4.29. Hence, Lukas Biomedical's PS Ratio for today is 5.73.
The historical rank and industry rank for Lukas Biomedical's PS Ratio or its related term are showing as below:
ROCO:6814'
s PS Ratio Range Over the Past 10 Years
Min: 4.35 Med: 6.18 Max: 11.96
Current: 5.73
During the past 8 years, Lukas Biomedical's highest PS Ratio was 11.96. The lowest was 4.35. And the median was 6.18.
ROCO:6814's PS Ratio is ranked better than 62% of 929
companies
in the Biotechnology industry
Industry Median: 9.03
vs ROCO:6814: 5.73
Lukas Biomedical Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Lukas Biomedical was -10.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -5.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -2.80% per year.
During the past 8 years, Lukas Biomedical's highest 3-Year average Revenue per Share Growth Rate was 4.70% per year. The lowest was -9.60% per year. And the median was 0.20% per year.
Back to Basics: PS Ratio
Lukas Biomedical (ROCO:6814) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lukas Biomedical PS Ratio Related Terms
Lukas Biomedical PS Ratio Historical Data
* Premium members only.
The historical data trend for Lukas Biomedical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6814 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Lukas Biomedical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lukas Biomedical PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lukas Biomedical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lukas Biomedical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lukas Biomedical's Share Price of today is NT$24.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lukas Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$4.29.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lukas Biomedical (ROCO:6814) has a PS Ratio of 5.73 as of Jul. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lukas Biomedical and its competitors. This is near median its historical median of 6.18. Over the past decade, Lukas Biomedical's PS Ratio has ranged from 4.35 to 11.96. According to the industry distribution chart, Lukas Biomedical ranks #353 out of 929 companies in the Biotechnology industry, placing it in the top 38%.
Is Lukas Biomedical's PS Ratio too high?
Lukas Biomedical's current PS Ratio of 5.73 is near median its 10-year median of 6.18. Over the past 10 years, this metric has ranged from a low of 4.35 to a high of 11.96. The Biotechnology industry median PS Ratio is 9.03. Lukas Biomedical's value of 5.73 is 36.5% below this industry median. Based on the distribution chart, Lukas Biomedical ranks #353 out of 929 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lukas Biomedical ranks #353 out of 929 companies for PS Ratio. This puts Lukas Biomedical in the upper half of its industry. The industry median PS Ratio is 9.03. Lukas Biomedical's value of 5.73 is 36.5% below this benchmark. Historically, Lukas Biomedical's own PS Ratio has ranged from 4.35 to 11.96 over the past decade. While the company's 10-year median is 6.18 vs. the industry median of 9.03, Lukas Biomedical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.03, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lukas Biomedical's current PS Ratio of 5.73 is 36.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lukas Biomedical and its competitors. For the Biotechnology industry, the median PS Ratio is 9.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lukas Biomedical's current PS Ratio is 5.73, which is near median its own 10-year median of 6.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.75, compared to a current price of NT$24.55 — trading 12.9% above its estimated fair value. The current PS Ratio is 5.73, which is near median its 10-year median of 6.18 and 36.5% below the Biotechnology industry median of 9.03. Lukas Biomedical's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current PS Ratio is 5.73 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?
Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued.
The current stock price of NT$24.55 is trading 12.9% above its estimated GF Value™ of NT$21.75.
GuruFocus considers Lukas Biomedical to be Modestly Overvalued.
Key valuation signals for ROCO:6814:
PS Ratio: 5.73 (near median its 10-year median of 6.18)
GF Value™: NT$21.75 vs. price of NT$24.55 (12.9% above fair value)
Industry Position: 36.5% below the Biotechnology median (#353 of 929)
No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score
Get the complete analysis for ROCO:6814
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6814 has been successfully added to your 
